News
October 23, 2025
DIAGNOS to Extend Exercise Period of Stock Warrants Expiring on November 9, 2025
BROSSARD, Quebec, Oct. 22, 2025 (GLOBE NEWSWIRE) — Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of critical health issues using advanced technology based on Artificial Intelligence (AI), announces that it intends to extend the exercise period of an aggregate of 1,125,000 stock warrants (each [...]
DIAGNOS Inc., a Quebec-based company specializing in AI-powered early disease detection, announced today its intention to extend the exercise period for a significant number of outstanding stock warrants. The warrants, totaling 1,125,000, were originally set to expire on November 9, 2025.
This decision, revealed in a press release issued on October 22, 2025, aims to provide warrant holders with additional time to potentially purchase common shares of DIAGNOS. The company believes this extension will be beneficial to both the warrant holders and the Corporation itself. While the specific new expiry date has yet to be formally announced, the company indicated further details will be released in the coming days.
Stock warrants are essentially options that give the holder the right, but not the obligation, to buy a company's stock at a predetermined price within a specific timeframe. Extending the exercise period allows warrant holders to wait and see how the company performs before deciding whether or not to exercise their right to purchase the shares.
DIAGNOS has been gaining recognition for its innovative use of artificial intelligence in the early detection of critical health problems. Their technology aims to improve patient outcomes by enabling earlier diagnosis and intervention. The company is publicly traded on the TSX Venture Exchange under the symbol ADK, as well as on the OTCQB market in the United States under the symbol DGNOF, and on the Frankfurt Stock Exchange under the symbol 4D4A.
The extension of the warrant exercise period represents a strategic move by DIAGNOS. By providing warrant holders with more flexibility, the company hopes to potentially generate additional capital in the future should those warrants be exercised. The market will be watching closely for further details regarding the new expiry date and any other relevant conditions associated with the extension. Investors and warrant holders are encouraged to monitor DIAGNOS's official announcements for updates.
This decision, revealed in a press release issued on October 22, 2025, aims to provide warrant holders with additional time to potentially purchase common shares of DIAGNOS. The company believes this extension will be beneficial to both the warrant holders and the Corporation itself. While the specific new expiry date has yet to be formally announced, the company indicated further details will be released in the coming days.
Stock warrants are essentially options that give the holder the right, but not the obligation, to buy a company's stock at a predetermined price within a specific timeframe. Extending the exercise period allows warrant holders to wait and see how the company performs before deciding whether or not to exercise their right to purchase the shares.
DIAGNOS has been gaining recognition for its innovative use of artificial intelligence in the early detection of critical health problems. Their technology aims to improve patient outcomes by enabling earlier diagnosis and intervention. The company is publicly traded on the TSX Venture Exchange under the symbol ADK, as well as on the OTCQB market in the United States under the symbol DGNOF, and on the Frankfurt Stock Exchange under the symbol 4D4A.
The extension of the warrant exercise period represents a strategic move by DIAGNOS. By providing warrant holders with more flexibility, the company hopes to potentially generate additional capital in the future should those warrants be exercised. The market will be watching closely for further details regarding the new expiry date and any other relevant conditions associated with the extension. Investors and warrant holders are encouraged to monitor DIAGNOS's official announcements for updates.
Category:
Politics